Anti-PD-1/anti-LAG-3 combination highly effective in HER2-negative breast cancer Presented ByProf. Claudine Isaacs, Georgetown University Medical Center, DC, USA TrialPhase 2, I-SPY 2 ConferenceSABCS 2022 1 February, 2023 17:42